GENSIGHT BIOLOGICS SA (SIGHT.PA) Stock Price, Forecast & Analysis
EPA:SIGHT • FR0013183985
SIGHT.PA Key Statistics, Chart & Performance
The current stock price of SIGHT.PA is 0.081 EUR. In the past month the price increased by 0.12%. In the past year, price decreased by -66.16%.
SIGHT.PA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to SIGHT.PA. When comparing the yearly performance of all stocks, SIGHT.PA is a bad performer in the overall market: 96.94% of all stocks are doing better.
SIGHT.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to SIGHT.PA. Both the profitability and financial health of SIGHT.PA have multiple concerns.
SIGHT.PA Financial Highlights
Over the last trailing twelve months SIGHT.PA reported a non-GAAP Earnings per Share(EPS) of -0.13. The EPS increased by 78.83% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -205.69% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
SIGHT.PA Forecast & Estimates
11 analysts have analysed SIGHT.PA and the average price target is 0.44 EUR. This implies a price increase of 441.48% is expected in the next year compared to the current price of 0.081.
For the next year, analysts expect an EPS growth of -2.06% and a revenue growth -3.66% for SIGHT.PA
SIGHT.PA Ownership
SIGHT.PA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 27.69 | 43.591B | ||
| ARGX | ARGENX SE | 27.81 | 43.541B | ||
| 22UA | BIONTECH SE-ADR | N/A | 22.326B | ||
| ABVX | ABIVAX SA | N/A | 8.714B | ||
| 2X1 | ABIVAX SA | N/A | 8.698B | ||
| GXE | GALAPAGOS NV | N/A | 1.885B | ||
| GLPG | GALAPAGOS NV | N/A | 1.871B | ||
| IVA | INVENTIVA SA | N/A | 1.166B | ||
| 6IV | INVENTIVA SA | N/A | 1.112B | ||
| NANO | NANOBIOTIX | N/A | 1.031B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About SIGHT.PA
Company Profile
GenSight Biologics SA is a clinical-stage gene therapy company, which engages in research and development of novel therapies for mitochondrial and neurodegenerative diseases of the eye. The company is headquartered in Paris, Ile-De-France and currently employs 13 full-time employees. The company went IPO on 2016-07-13. The firm develops and commercializes gene therapy-based treatments of retinal degenerative diseases. The company develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The firm intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).
Company Info
GENSIGHT BIOLOGICS SA
74 Rue du Faubourg Saint-Antoine
Paris ILE-DE-FRANCE FR
Employees: 13
Phone: 33176217220
GENSIGHT BIOLOGICS SA / SIGHT.PA FAQ
What does SIGHT do?
GenSight Biologics SA is a clinical-stage gene therapy company, which engages in research and development of novel therapies for mitochondrial and neurodegenerative diseases of the eye. The company is headquartered in Paris, Ile-De-France and currently employs 13 full-time employees. The company went IPO on 2016-07-13. The firm develops and commercializes gene therapy-based treatments of retinal degenerative diseases. The company develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The firm intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).
What is the stock price of GENSIGHT BIOLOGICS SA today?
The current stock price of SIGHT.PA is 0.081 EUR. The price decreased by -1.1% in the last trading session.
Does GENSIGHT BIOLOGICS SA pay dividends?
SIGHT.PA does not pay a dividend.
How is the ChartMill rating for GENSIGHT BIOLOGICS SA?
SIGHT.PA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Where is GENSIGHT BIOLOGICS SA (SIGHT.PA) stock traded?
SIGHT.PA stock is listed on the Euronext Paris exchange.
How is the valuation of GENSIGHT BIOLOGICS SA (SIGHT.PA) based on its PE ratio?
GENSIGHT BIOLOGICS SA (SIGHT.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.13).
What is GENSIGHT BIOLOGICS SA worth?
GENSIGHT BIOLOGICS SA (SIGHT.PA) has a market capitalization of 17.89M EUR. This makes SIGHT.PA a Nano Cap stock.